• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

接受干扰素-β治疗的伊朗多发性硬化症患者的IFNAR1表达水平。

IFNAR1 expression level in Iranian multiple sclerosis patients treated with IFN-B.

作者信息

Sayad Arezou, Kelarijani Mohsen Khakzad, Sajjadi Elham, Taheri Mohammad

机构信息

Department of Medical Genetics, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

出版信息

Hum Antibodies. 2017;26(1):17-22. doi: 10.3233/HAB-170316.

DOI:10.3233/HAB-170316
PMID:28282804
Abstract

BACKGROUND

Multiple sclerosis (MS) as an auto-immune disease is an inflammatory, demyelinating disease of the central nervous system. Certain genes have shown to be involved in the initiation of MS but the specific role of some of them, e.g. IFNAR1 has not been identified in certain populations yet.

OBJECTIVE

The IFNAR1 as a type I membrane protein shapes one of the two chains of a receptor for interferons alpha and beta.

METHODS

To find out how IFNAR1 functions in the Iranian population, the researchers compared the expression level of this gene in relapsing-remitting MS (RR-MS) samples with normal individuals. RNA from the whole blood of 50 RR-MS patients and 50 normal controls were extracted. All patients were HLA-DRB1*15 negative and were responders to interferon-beta with a normal vitamin D level. The level of IFNAR1 gene expression was measured using quantitative RT-PCR.

RESULTS

According to the results the RR-MS patients manifested a statistically higher expression level of IFNAR1 than their normal counterparts (p= 0.012). Age-wise, females between the ages, 30 to 40 had a significant increase (p= 0.046) but males under 30 showed a statistically meaningful decrease in the expression level (p= 0.04). In terms of sex, only the female patients manifested a statistically significant increase in IFNAR1 (p= 0.004).

CONCLUSIONS

The overall results show an increase in IFNAR1 level in MS patients treated with IFN-B.

摘要

背景

多发性硬化症(MS)作为一种自身免疫性疾病,是中枢神经系统的一种炎症性脱髓鞘疾病。某些基因已被证明与MS的发病有关,但其中一些基因的具体作用,例如IFNAR1,在某些人群中尚未明确。

目的

IFNAR1作为一种I型膜蛋白,构成了干扰素α和β受体的两条链之一。

方法

为了了解IFNAR1在伊朗人群中的作用,研究人员比较了复发缓解型MS(RR-MS)样本与正常个体中该基因的表达水平。提取了50例RR-MS患者和50例正常对照者全血中的RNA。所有患者均为HLA-DRB1*15阴性,对干扰素-β有反应,维生素D水平正常。使用定量RT-PCR测量IFNAR1基因的表达水平。

结果

根据结果,RR-MS患者的IFNAR1表达水平在统计学上高于正常对照者(p = 0.012)。按年龄划分,30至40岁的女性有显著升高(p = 0.046),但30岁以下的男性表达水平在统计学上有显著下降(p = 0.04)。就性别而言,只有女性患者的IFNAR1有统计学上的显著升高(p = 0.004)。

结论

总体结果显示,接受IFN-B治疗的MS患者中IFNAR1水平升高。

相似文献

1
IFNAR1 expression level in Iranian multiple sclerosis patients treated with IFN-B.接受干扰素-β治疗的伊朗多发性硬化症患者的IFNAR1表达水平。
Hum Antibodies. 2017;26(1):17-22. doi: 10.3233/HAB-170316.
2
Up regulation of MMP9 gene expression in female patients with multiple sclerosis.多发性硬化症女性患者中MMP9基因表达的上调
Hum Antibodies. 2016;24(3-4):59-64. doi: 10.3233/HAB-160292.
3
Increased expression ratio of matrix metalloproteinase-9 (MMP9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) RNA levels in Iranian multiple sclerosis patients.伊朗多发性硬化症患者中基质金属蛋白酶-9(MMP9)与基质金属蛋白酶组织抑制剂(TIMP-1)RNA水平的表达比率增加。
Hum Antibodies. 2016;24(3-4):65-70. doi: 10.3233/HAB-160296.
4
Down-regulation of CYP27B1 gene expression in Iranian patients with relapsing-remitting multiple sclerosis.伊朗复发缓解型多发性硬化症患者中CYP27B1基因表达的下调
Hum Antibodies. 2016;24(3-4):71-76. doi: 10.3233/HAB-160297.
5
Inverse Relation between MxA Gene Expression and Age in Multiple Sclerosis Patients Reveals a Gender Difference in Response to Interferon Therapy.多发性硬化症患者中MxA基因表达与年龄的负相关揭示了干扰素治疗反应中的性别差异。
Iran J Allergy Asthma Immunol. 2017 Feb;16(1):21-27.
6
MicroRNA-29b variants and MxA expression change during interferon beta therapy in patients with relapsing-remitting multiple sclerosis.微小 RNA-29b 变体和 MxA 表达在复发缓解型多发性硬化症患者接受干扰素β治疗期间的变化。
Mult Scler Relat Disord. 2019 Oct;35:241-245. doi: 10.1016/j.msard.2019.07.034. Epub 2019 Jul 31.
7
Modulation of IFNAR1 mRNA expression in multiple sclerosis patients.多发性硬化症患者中IFNAR1 mRNA表达的调节
J Neuroimmunol. 2008 Jun 15;197(1):54-62. doi: 10.1016/j.jneuroim.2008.03.019. Epub 2008 May 15.
8
TRAILR1 (rs20576) and GRIA3 (rs12557782) are not associated with interferon-β response in multiple sclerosis patients.TRAILR1(rs20576)和GRIA3(rs12557782)与多发性硬化症患者的干扰素-β反应无关。
Mol Biol Rep. 2020 Dec;47(12):9659-9665. doi: 10.1007/s11033-020-06026-w. Epub 2020 Dec 2.
9
HLA-DRB1 does not have a role in clinical response to interferon-beta among Iranian multiple sclerosis patients.在伊朗多发性硬化症患者中,HLA - DRB1在对β干扰素的临床反应中不起作用。
J Neurol Sci. 2015 May 15;352(1-2):37-40. doi: 10.1016/j.jns.2015.03.004. Epub 2015 Mar 9.
10
Immune response genes receptors expression and polymorphisms in relation to multiple sclerosis susceptibility and response to INF-β therapy.免疫反应基因受体的表达及多态性与多发性硬化症易感性和对INF-β治疗反应的关系
IUBMB Life. 2016 Sep;68(9):727-34. doi: 10.1002/iub.1530. Epub 2016 Jun 27.

引用本文的文献

1
Genetic and Molecular Biology of Multiple Sclerosis Among Iranian Patients: An Overview.多发性硬化症患者的遗传与分子生物学:综述。
Cell Mol Neurobiol. 2020 Jan;40(1):65-85. doi: 10.1007/s10571-019-00731-2. Epub 2019 Sep 3.
2
Validation of a cell-based colorimetric reporter gene assay for the evaluation of Type I Interferons.用于评估I型干扰素的基于细胞的比色报告基因检测法的验证
Biotechnol Rep (Amst). 2019 Apr 18;22:e00331. doi: 10.1016/j.btre.2019.e00331. eCollection 2019 Jun.